Keros Therapeutics, Inc. (KROS)
11.23
+0.16
(+1.45%)
USD |
NASDAQ |
Sep 02, 16:00
11.23
0.00 (0.00%)
After-Hours: 19:41
Keros Therapeutics Research and Development Expense (Annual) : 127.09M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 127.09M |
| December 31, 2024 | 173.63M |
| December 31, 2023 | 135.26M |
| December 31, 2022 | 87.26M |
| Date | Value |
|---|---|
| December 31, 2021 | 55.14M |
| December 31, 2020 | 33.86M |
| December 31, 2019 | 17.38M |
| December 31, 2018 | 10.11M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Incyte Corp. | 1.984B |
| Nurix Therapeutics, Inc. | 308.16M |
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |
| Anika Therapeutics, Inc. | 25.77M |